Mikhail Blagosklonny is renowned scientist and researcher with massive records in undertaking studies on cancer and aging. He serves as the professor of oncology at the Roswell Park Cancer Institute, New York. Blagosklonny studied at the First Pavlov State Medical University of St. Petersburg where he earned his Master’s degree in Internal Medicine and a PhD in Cardiology and Experimental Medicine.
Mikhail Blagosklonny began his career in 2002 as an associate professor of medicine at the Valhalla-based New York Medical College. He later took up a position of senior scientist at the Ordway Research Institute in Albany, New York where he worked until 2009 when he moved to Roswell Park Cancer Institute as the professor of oncology. Blogosklonny’s work involves research on cancer and the targeted therapies that aid protection for normal cells in addition to underlying issues with aging (biogerontology).
Rapamycin and Aging
Blagosklonny has made progression in the field of aging with his formulated hypothesis on LinkedIn indicating a possible role of TOR to aging and cancer. He is among the active advocates of use of rapamycin, which is a popular cancer drug and suggests that the drug has possible life extension effects.
Blagosklonny is editor-in-chief of Cell Cycle, Aging, and Oncotarget on Nature. He also serves as member of the editorial board at Cell Death & Differentiation and an associate editor of Cancer Biology & Therapy.
Oncotarget is a traditional multidisciplinary journal offered to the public free of charge. It publishes online papers on a weekly basis and may be printed out for special use.
The mission of Oncotarget is to enable people to access scientific results quickly and widely. It also yearns to share insightful that impact research on tandfonline.com, allow sharing for exceptional discoveries, eliminate boundaries between specialists, and to fight diseases through application clinical and basic science.
Oncotarget Launches Sections beyond Oncology
Mikhail Blagosklonny’s success with Oncotarget has seen the launch of sections beyond oncology. It now provides Free Almetric Article Reports on Google in the new line of journals that give a real-time tracking of contents on traditional media channels as well as digital platforms.